Pfizer is spending more than $7 billion to buy biotech Metsera to try to catch cup in the obesity drug market.
Get this delivered to your inbox, and more info about our products and services.
Pfizer said it would pay $86.25 per share in cash, a premium of 3.69% to Metsera's Friday close.
Metsera has no products on the market, but it is developing oral and injectable treatments.
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity…
Pfizer pagherà fino a 86,25 dollari ad azione, di cui 65,60 dollari ad azione in contanti, più potenziali pagamenti aggiuntivi…
Deal would be the biggest by a large pharma company buying a foothold in the lucrative weight-loss drug market
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…
